West Nile Virus Antibody, IgM by ELISA, CSF
Also known as: WNIL IGM
Use
This test is intended for the semi-quantitative detection of West Nile virus-specific IgM in cerebrospinal fluid (CSF) specimens where there is clinical suspicion of West Nile virus infection. The presence of IgM antibodies may indicate a current or recent infection with the virus. However, consideration must be given to potential cross-reactivity with other viruses in the Flaviviridae family (such as St. Louis encephalitis virus), contamination by blood, or transfer of serum antibodies across the blood-brain barrier.
Special Instructions
Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory. This test should not be used solely for quantitative purposes, nor should results be used in isolation from clinical history or other data.
Limitations
The test is developed by ARUP Laboratories as an LDT and has not been cleared or approved by the FDA. Cross-reactivity with other members of the Flaviviridae family might occur, and serologic testing specific to these species should be considered. A false positive rate of 2-3% has been demonstrated with the Focus Diagnostics ELISA assay. It's important to repeat testing in 10-14 days if the results are equivocal.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 39573-1
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated. New York State Clients: Frozen
Causes for Rejection
Bacterially contaminated, heat-inactivated, hemolyzed or xanthochromic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |